Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

BSH 2019 | Lessons learned from the CLL CLARITY study and ongoing follow-up

Talha Munir • 1 Apr 2019
BSH 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax
CLARITY

Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the lessons that we have learned from the Bloodwise Trials Acceleration Programme (TAP) CLARITY study (ISCRTN13751862), which investigated venetoclax in combination with ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Dr Munir also discusses the ongoing follow-up analysis to see how durable MRD negativity was. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Talha Munir

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
The Phase III STATIC trial: stopping therapy to avoid treatment resistance in CLL 1:30
The Phase III STATIC trial: stopping therapy to avoid treatment resistance in CLL
Talha Munir • 14 Sep 2025
The comparative efficacy of zanubrutinib versus fixed-duration AV in frontline CLL 1:33
The comparative efficacy of zanubrutinib versus fixed-duration AV in frontline CLL
Talha Munir • 14 Sep 2025
MRD-guided ibrutinib-venetoclax versus ibrutinib or FCR for previously untreated CLL: FLAIR trial 1:39
MRD-guided ibrutinib-venetoclax versus ibrutinib or FCR for previously untreated CLL: FLAIR trial
Talha Munir • 14 Sep 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals